ストックスクリーナーアプリを入手
17.15
2.11%
-0.37
アフターアワーズ：
17.48
0.33
+1.92%
前日終値:
$17.52
開ける：
$17.23
24時間の取引高:
1.42M
Relative Volume:
0.76
時価総額：
$2.51B
収益：
$340.81M
当期純損益:
$-419.65M
株価収益率:
-6.0175
EPS:
-2.85
ネットキャッシュフロー:
$-402.10M
1週間 パフォーマンス:
+19.01%
1か月 パフォーマンス:
+14.49%
6か月 パフォーマンス:
+20.27%
1年 パフォーマンス:
-42.12%
1日の値動き範囲:
$16.66
$17.84
1週間の範囲:
$13.75
$18.70
52週間の値動き範囲:
$10.57
$29.80
Denali Therapeutics Inc Stock (DNLI) Company Profile
名前
Denali Therapeutics Inc
セクター
電話
(650) 866-8547
住所
161 OYSTER POINT BLVD., SOUTH SAN FRANCISCO
DNLI を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
DNLI
Denali Therapeutics Inc
|
17.15 | 2.57B | 340.81M | -419.65M | -402.10M | -2.85 |
|
VRTX
Vertex Pharmaceuticals Inc
|
434.52 | 110.16B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
694.99 | 71.65B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
453.97 | 59.81B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
891.73 | 54.79B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
368.36 | 41.77B | 4.56B | -176.77M | 225.30M | -1.7177 |
Denali Therapeutics Inc Stock (DNLI) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-04-10 | アップグレード | Cantor Fitzgerald | Neutral → Overweight |
| 2025-03-07 | 再開されました | Morgan Stanley | Overweight |
| 2025-02-11 | 開始されました | Deutsche Bank | Buy |
| 2025-01-07 | 開始されました | Robert W. Baird | Outperform |
| 2025-01-03 | 開始されました | William Blair | Outperform |
| 2024-12-16 | アップグレード | Stifel | Hold → Buy |
| 2024-10-10 | 再開されました | Raymond James | Mkt Perform |
| 2024-10-07 | ダウングレード | Cantor Fitzgerald | Overweight → Neutral |
| 2023-12-13 | 開始されました | Citigroup | Buy |
| 2023-11-20 | 再開されました | JP Morgan | Overweight |
| 2023-10-24 | 再開されました | Cantor Fitzgerald | Overweight |
| 2023-09-06 | 開始されました | B. Riley Securities | Buy |
| 2023-01-30 | 開始されました | SVB Securities | Outperform |
| 2022-12-05 | 開始されました | Cowen | Outperform |
| 2022-11-02 | アップグレード | BTIG Research | Neutral → Buy |
| 2022-11-02 | 開始されました | BofA Securities | Buy |
| 2022-06-23 | 開始されました | Berenberg | Buy |
| 2021-12-10 | 再開されました | Raymond James | Mkt Perform |
| 2021-09-21 | 開始されました | Oppenheimer | Outperform |
| 2021-09-01 | 開始されました | SMBC Nikko | Outperform |
| 2021-05-18 | 開始されました | UBS | Buy |
| 2021-02-26 | 繰り返されました | H.C. Wainwright | Buy |
| 2021-02-10 | アップグレード | Cantor Fitzgerald | Neutral → Overweight |
| 2020-11-11 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-10-16 | ダウングレード | BTIG Research | Buy → Neutral |
| 2020-09-14 | 再開されました | JP Morgan | Overweight |
| 2020-08-20 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-03-13 | アップグレード | Evercore ISI | In-line → Outperform |
| 2020-02-28 | アップグレード | Wedbush | Neutral → Outperform |
| 2020-02-24 | 開始されました | Jefferies | Buy |
| 2020-02-19 | 開始されました | Stifel | Hold |
| 2020-01-27 | アップグレード | Goldman | Neutral → Buy |
| 2019-09-26 | 開始されました | Wedbush | Neutral |
| 2019-09-13 | 開始されました | Nomura | Buy |
| 2019-08-09 | 開始されました | BTIG Research | Buy |
| 2019-06-26 | 開始されました | H.C. Wainwright | Buy |
| 2018-11-15 | 開始されました | Cantor Fitzgerald | Overweight |
| 2018-11-12 | 開始されました | Janney | Buy |
| 2018-03-12 | ダウングレード | Evercore ISI | Outperform → In-line |
| 2018-01-02 | 開始されました | Evercore ISI | Outperform |
| 2018-01-02 | 開始されました | Goldman | Neutral |
| 2018-01-02 | 開始されました | JP Morgan | Overweight |
| 2018-01-02 | 開始されました | Morgan Stanley | Overweight |
すべてを表示
Denali Therapeutics Inc (DNLI) 最新ニュース
How Denali Therapeutics Inc. (4DN) stock gains from tech spendingQuarterly Portfolio Report & Consistent Growth Equity Picks - newser.com
The Escalator: Genentech, Denali Therapeutics, Eli Lilly and more - Medical Marketing and Media
Will Denali Therapeutics Inc. stock gain from lower inflationBond Market & Weekly Momentum Stock Picks - newser.com
Will Denali Therapeutics Inc. (4DN) stock beat international competitionTreasury Yields & High Accuracy Investment Entry Signals - newser.com
How Denali Therapeutics Inc. (4DN) stock performs in easing cycles2025 Major Catalysts & Fast Gain Stock Tips - newser.com
Is Denali Therapeutics Inc. stock a contrarian buyAnalyst Upgrade & Expert Curated Trade Setups - newser.com
Why Denali Therapeutics Inc. stock is favored by pension funds2025 Investor Takeaways & Community Consensus Trade Signals - newser.com
Is Denali Therapeutics Inc. (4DN) stock positioned for digital growth era2025 Winners & Losers & Comprehensive Market Scan Insights - newser.com
Is Denali Therapeutics Inc. stock a dividend growth opportunityWeekly Gains Report & Weekly Setup with High ROI Potential - newser.com
H.C. Wainwright Reiterates “Buy” Rating on Denali Therapeutics (DNLI) With $32 PT Following Q3 Results - Yahoo Finance
Will Denali Therapeutics Inc. stock outperform Nasdaq index2025 Volatility Report & Safe Capital Growth Plans - newser.com
Will Denali Therapeutics Inc. stock rally after Fed decisions2025 Trading Volume Trends & Safe Entry Trade Reports - newser.com
Is Denali Therapeutics Inc. stock ready for a breakoutWeekly Trade Summary & Real-Time Buy Signal Notifications - newser.com
Denali Therapeutics (DNLI): Exploring Valuation After Recent Share Price Rebound - Yahoo Finance
15 Stocks Set to Explode in 2026 - Insider Monkey
Does Denali Therapeutics Inc. qualify in momentum factor screeningBuy Signal & Comprehensive Market Scan Insights - newser.com
Is Denali Therapeutics Inc. stock supported by strong cash flowsWeekly Market Summary & Daily Growth Stock Tips - newser.com
DNLI Posts Narrower-Than-Expected Q3 Loss, Advances MPS IIIA Drug - MSN
Can Denali Therapeutics Inc. (4DN) stock resist broad market declinesMarket Movers & Accurate Buy Signal Notifications - newser.com
Will Denali Therapeutics Inc. (4DN) stock enhance shareholder valueEarnings Overview Report & Technical Pattern Based Signals - newser.com
Denali Therapeutics announces board and leadership changes By Investing.com - Investing.com Canada
Comparing Denali Therapeutics Inc. in custom built stock radarsShare Buyback & Consistent Income Trade Recommendations - newser.com
Denali Therapeutics Reports Increased Losses Amid Strategic Collaborations - TipRanks
Decoding Denali Therapeutics Inc (DNLI): A Strategic SWOT Insigh - GuruFocus
Denali Therapeutics Announces Board and Executive Leadership Updates - The Globe and Mail
Denali Therapeutics: Promising Pipeline and Strategic Progress Justify Buy Rating - TipRanks
Denali Therapeutics is losing Carole Ho, as she heads to Lilly as head of neuroscienceSan Francisco Business Times - The Business Journals
Denali Therapeutics Q3 net loss widens to $126.9 mln - MarketScreener
Denali Therapeutics Inc reports results for the quarter ended September 30Earnings Summary - TradingView
[10-Q] Denali Therapeutics Inc. Quarterly Earnings Report | DNLI SEC FilingForm 10-Q - Stock Titan
Denali Therapeutics Reports Third Quarter 2025 Financial Results and Business Highlights - The Manila Times
Denali Therapeutics announces board and leadership changes - Investing.com
[8-K] Denali Therapeutics Inc. Reports Material Event | DNLI SEC FilingForm 8-K - Stock Titan
Will Denali Therapeutics Inc. (4DN) stock outperform small cap peersJuly 2025 News Drivers & Real-Time Buy Signal Alerts - newser.com
Why analysts remain bullish on Denali Therapeutics Inc. stockShort Setup & Low Drawdown Momentum Ideas - newser.com
How Denali Therapeutics Inc. stock compares to market leaders2025 Price Momentum & Daily Oversold Bounce Ideas - Fundação Cultural do Pará
Denali Therapeutics Inc (DNLI) 財務データ
収益
当期純利益
現金流量
EPS
Denali Therapeutics Inc (DNLI) インサイダートレーディング
0.35%
0.75%
大文字化:
|
ボリューム (24 時間):